Le Lézard
Classified in: Health, Science and technology
Subject: PDT

UC Irvine Spinout, Debut, Seeks to Transform Chemical Manufacturing Industry

SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Debut Biotechnology, a startup located in San Diego, California, has exclusively licensed two inventions from the University of California, Irvine (UCI) that will allow continuous manufacturing in the pharmaceutical, alcoholic beverage, and cannabinoid industries. Utilizing easy-to-use enzyme cartridges, complex pharmaceuticals will be created using only cells, alcohol will be created in minutes, and cannabinoids will be manufactured without the plant.

Debut Biotechnology Team (Left to Right): Dr. Nicholas Brideau (Senior Scientist), Brady Beauchamp (Co-Founder & COO), Megha Rawal (Research Scientist), Dr. Gregory Weiss (Co-Founder & Advisor), Dr. Joshua Britton (Co-Founder & CEO).

"We believe the way chemicals and pharmaceuticals are created in the next ten years will be performed using enzymes," said Dr. Joshua Britton, founder, Debut Biotechnology. "Enzymes are beautiful machines found in nature that perform complex chemical transformations most chemists can only dream about. We use these machines to construct pharmaceuticals and high value molecules thus allowing us to re-think chemical synthesis." 

The way in which chemicals and pharmaceuticals are made is undergoing a paradigm shift. Reactions are typically done in large containers known as 'batch' reactors. However, continuous manufacturing is changing the way we think about making chemicals. While companies in this area are focused on translating traditional chemistry into continuous manufacturing, Debut sees a different approach and outcome for the future of manufacturing.

"Over the next ten years, chemical manufacturing will look much different than it does today. At Debut, we create products that enable this forthcoming change," Britton said.

Britton's words echo those of former FDA Commissioner Scott Gottlieb who said, "Continuous manufacturing helps to ensure consistently-made products, allows manufacturers to more easily scale their manufacturing operations to meet demand, and can help reduce drug shortages by minimizing operational stops and starts."

Debut biotechnology is housed at BioLabs in San Diego and aims for their products to decrease process costs, time, energy, land usage, and water typically associated with chemical manufacturing. 

"We are excited that Debut is moving this technology from the labs at UCI to realize its transformative potential in continuous manufacturing, thereby benefitting the economy and society at large," noted Casie Kelly, assistant director of Licensing, UCI Beall Applied Innovation.

More information on Debut Biotechnology and their technology can be found at www.debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology, Inc. located in San Diego, Calif., creates advanced manufacturing processes for high value molecules by combining immobilized enzymes with continuous manufacturing across a wide range of industries.

Contact: brady@debutbiotech.com


SOURCE Debut Biotechnology

These press releases may also interest you

at 02:19
Isofol Medical AB (publ), , today announced the successful completion of Japan's Pharmaceutical and Medical Devices Agency (PMDA) review of the Clinical Trial Notification (CTN), allowing the start of the pivotal Phase 3 AGENT clinical study in...

at 02:11
"We continue to show strong organic sales growth and improved margins in the third quarter", says Mattias Perjos, President & CEO at Getinge. "The underlying cash flow remains strong despite that we seasonally are tying up more capital in the third...

at 01:54
UCB (Euronext Brussels: UCB) and Amgen today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion recommending Marketing...

at 01:43
Reference is made to the stock exchange release from Nordic Nanovector ASA (OSE: NANO) ("Nordic Nanovector" or the "Company"), a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through...

at 01:00
Amgen and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Marketing...

17 oct 2019
Xcovery Holdings, Inc., an oncology-focused biopharmaceutical company, today announced that ensartinib, the company's lead drug candidate, demonstrated efficacy and safety in patients with crizotinib-refractory, anaplastic lymphoma kinase (ALK)...

News published on 18 september 2019 at 20:42 and distributed by: